.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Farmers Insurance
Moodys
Merck
Chinese Patent Office
Citi
UBS
US Department of Justice
Fuji
US Army

Generated: November 21, 2017

DrugPatentWatch Database Preview

RAZADYNE Drug Profile

« Back to Dashboard

Which patents cover Razadyne, and what generic Razadyne alternatives are available?

Razadyne is a drug marketed by Janssen Pharms and is included in three NDAs. There are three patents protecting this drug and three Paragraph IV challenges.

This drug has forty-four patent family members in thirty-three countries and one supplementary protection certificate in one country.

The generic ingredient in RAZADYNE is galantamine hydrobromide. There are fifteen drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the galantamine hydrobromide profile page.

Pharmacology for RAZADYNE

Medical Subject Heading (MeSH) Categories for RAZADYNE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Janssen Pharms
RAZADYNE
galantamine hydrobromide
SOLUTION;ORAL021224-001Jun 22, 2001DISCNNoNo► Subscribe► Subscribe► Subscribe
Janssen Pharms
RAZADYNE
galantamine hydrobromide
TABLET;ORAL021169-003Feb 28, 2001ABRXYesNo► Subscribe► Subscribe ► Subscribe
Janssen Pharms
RAZADYNE
galantamine hydrobromide
TABLET;ORAL021169-002Feb 28, 2001ABRXYesNo► Subscribe► SubscribeY ► Subscribe
Janssen Pharms
RAZADYNE ER
galantamine hydrobromide
CAPSULE, EXTENDED RELEASE;ORAL021615-001Apr 1, 2005ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Janssen Pharms
RAZADYNE
galantamine hydrobromide
TABLET;ORAL021169-001Feb 28, 2001ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Janssen Pharms
RAZADYNE
galantamine hydrobromide
TABLET;ORAL021169-001Feb 28, 2001ABRXYesYes► Subscribe► Subscribe ► Subscribe
Janssen Pharms
RAZADYNE
galantamine hydrobromide
TABLET;ORAL021169-003Feb 28, 2001ABRXYesNo► Subscribe► SubscribeY ► Subscribe
Janssen Pharms
RAZADYNE
galantamine hydrobromide
TABLET;ORAL021169-002Feb 28, 2001ABRXYesNo► Subscribe► Subscribe ► Subscribe
Janssen Pharms
RAZADYNE ER
galantamine hydrobromide
CAPSULE, EXTENDED RELEASE;ORAL021615-003Apr 1, 2005ABRXYesNo► Subscribe► SubscribeY ► Subscribe
Janssen Pharms
RAZADYNE ER
galantamine hydrobromide
CAPSULE, EXTENDED RELEASE;ORAL021615-002Apr 1, 2005ABRXYesNo► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for RAZADYNE

Drugname Dosage Strength RLD Submissiondate
galantamine hydrobromide Extended-release Capsules16 mg and 24 mgRazadyne ER3/11/2006
galantamine hydrobromide Extended-release Capsules8 mg Razadyne ER3/2/2006
galantamine hydrobromide Tablets4 mg, 8 mg and 12 mgRazadyne2/28/2005

International Patent Family for Tradename: RAZADYNE

Country Document Number Estimated Expiration
Spain2235234► Subscribe
Slovakia169698► Subscribe
Japan2000511918► Subscribe
South Korea20000015851► Subscribe
Poland189329► Subscribe
Canada2257431► Subscribe
Austria285777► Subscribe
Japan4172820► Subscribe
Eurasian Patent Organization001193► Subscribe
Israel127519► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: RAZADYNE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00140Netherlands► SubscribePRODUCT NAME: GALANTAMINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZUURADDITIEZOUT, IN HET BIJZONDER GALANTAMINE HYDROBROMIDE; NAT. REGISTRATION NO/DATE: RVG 29073 - RVG 29076 20030702; FIRST REGISTRATION: SE 15561 - 15565 20000225
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
AstraZeneca
Federal Trade Commission
Fish and Richardson
Citi
Queensland Health
US Department of Justice
Chubb
Moodys
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot